8-K: MindMed's MM120 Receives FDA Breakthrough Therapy Designation and Shows Positive Durability Data in Phase 2b Trial for Generalized Anxiety Disorder

MindMed's MM120 program for generalized anxiety disorder (GAD) has been granted breakthrough therapy designation by the FDA, and a Phase 2b trial demonstrated significant and durable efficacy through 12 weeks.

Summary

• MindMed announced that the FDA has granted breakthrough therapy designation to its MM120 program for the treatment of generalized anxiety disorder (GAD).
• The company's Phase 2b trial of MM120 in GAD met its key secondary endpoint, showing statistically significant durability of effect through Week 12.
• A single oral administration of MM120 100 micrograms demonstrated a 7.7-point improvement over placebo on the Hamilton Anxiety rating scale (HAM-A) at Week 12.
• The trial showed a 65% clinical response rate and a 48% clinical remission rate at Week 12.
• Clinical Global Impressions Severity (CGI-S) scores improved from 4.8 to 2.2 in the 100-microgram dose group at Week 12.
• MindMed plans to hold an End-of-Phase 2 meeting with the FDA in the first half of 2024 and initiate its Phase 3 clinical program in the second half of 2024.
• The company also terminated its at-the-market (ATM) offering of up to $100 million of common shares, but the sales agreement remains in effect.

Sentiment

Score: 9

Explanation: The document is highly positive due to the FDA breakthrough therapy designation, strong Phase 2b trial results, and the potential for a new treatment option for GAD. The termination of the ATM offering is a minor negative, but the overall tone is very optimistic.

Positives

• The FDA breakthrough therapy designation for MM120 highlights the potential of the treatment.
• The Phase 2b trial results show a strong and durable effect of MM120 on GAD symptoms.
• The 65% clinical response rate and 48% clinical remission rate are promising.
• The improvement in CGI-S scores indicates a significant clinical benefit.
• The PK bridging study suggests that the ODT formulation of MM120 has improved characteristics.
• The company has a diversified pipeline of clinical programs targeting significant unmet medical needs.
• The company expects its cash runway to extend through key clinical readouts and into 2026.

Negatives

• The company has a history of negative cash flows.
• The company has a limited operating history.
• The company has incurred and expects to incur future losses.
• The company is subject to risks associated with clinical trials and regulatory approval processes.
• The company operates in the novel psychedelic-inspired medicines industry which has heightened regulatory scrutiny.

Risks

• The company may face challenges in raising additional capital to fund its studies.
• There are risks associated with clinical trials and the regulatory approval process.
• The company operates in a novel industry with heightened regulatory scrutiny.
• The company's products may not achieve commercial viability.
• The company has a history of negative cash flows and may incur future losses.

Future Outlook

MindMed plans to hold an End-of-Phase 2 meeting with the FDA in the first half of 2024 and initiate its Phase 3 clinical program in the second half of 2024. The company is also evaluating additional clinical indications for MM120.

Management Comments

• David Feifel, MD, PhD, stated that the efficacy of MM120, sustained for 12 weeks after a single dose, is truly remarkable.
• Robert Barrow, Chief Executive Officer of MindMed, said that the FDA's decision to designate MM120 as a breakthrough therapy and the durability data from the Phase 2b study provide further validation of the important potential role this treatment can play in addressing the unmet need among individuals living with GAD.
• Reid Robison, MD, applauded the study design for isolating the effect of MM120 by removing confounding variables.

Industry Context

The announcement comes amid growing interest in psychedelic-inspired medicines for mental health disorders. The breakthrough therapy designation and positive trial results position MindMed as a potential leader in this emerging field, addressing a significant unmet need in the treatment of GAD, where there has been little innovation in the past several decades.

Comparison to Industry Standards

• The effect size of 0.81 observed in the MM120 trial is more than double the effect sizes typically seen with standard treatments for GAD, such as benzodiazepines (0.38), SSRIs (0.36), and buspirone (0.17).
• The study design aligns with the FDA's 2023 draft guidance for psychedelic drugs, which is a positive sign for regulatory approval.
• The trial's use of the Hamilton Anxiety Scale (HAM-A) as a primary endpoint is consistent with industry standards for GAD trials.
• The study's design, which excluded psychotherapy, allows for a clearer understanding of the drug's standalone effect, which is a unique approach compared to some other studies in the field.

Stakeholder Impact

• Shareholders are likely to react positively to the FDA breakthrough therapy designation and strong Phase 2b trial results.
• Patients with GAD may benefit from a new treatment option with potentially superior efficacy and durability.
• Employees of MindMed may be motivated by the positive progress of the MM120 program.
• The company's success could attract further investment and partnerships.

Next Steps

• MindMed plans to hold an End-of-Phase 2 meeting with the FDA in the first half of 2024.
• The company plans to initiate its Phase 3 clinical program for MM120 in the second half of 2024.
• The company will present full data from the Phase 2b trial at a scientific meeting.
• The company will evaluate additional clinical indications for MM120.

Key Dates

Keywords

MM120, Generalized Anxiety Disorder, GAD, Breakthrough Therapy Designation, Phase 2b Trial, Clinical Trial, Lysergide, MindMed, Mental Health, FDA, HAM-A, Clinical Remission, Clinical Response, Psychiatric Disorders, Drug Development